Korsana Biosciences receives Wedbush Outperform rating with $44 target
KRSA•Wedbush initiated coverage of Korsana Biosciences with an Outperform rating and a $44 price target.
Related News
LPL Financial adds Praxis Financial Partners to platform with $1.1 billion in assets
LPLA•
Ball Corp: UBS cuts target price to $63 from $66
BALL•
Ingredion Inc: UBS cuts target price to $104 from $108
INGR•
TELUS partners with AST SpaceMobile on direct-to-smartphone satellite connectivity in Canada
TU•
Copper firms on reduced likelihood of higher US interest rates
CPER•